TARRYTOWN, N.Y., Nov. 29, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it was named "Biotechnology Company of the Year" by Scrip Intelligence at the 8th annual Scrip Awards.
The Award recognizes the biotech firm that has achieved the most in the 12 months between June 1, 2011 and May 31, 2012. In presenting the award, Scrip said, "Regeneron has been transformed over the past year by the U.S. approval of its first major product. On the back of its highly successful launch, the company expects to become profitable for the first time in 2012."
Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, said, "We are honored to be recognized by Scrip, a leading industry publication. This has indeed been a transforming time for Regeneron, as we went from having one approved drug to three, advanced investigational drugs into Phase 3 trials, and created shareholder value that moved Regeneron into the top ranks of the biotechnology industry."
George D. Yancopoulos, M.D., Ph.D., President, Regeneron Laboratories and Chief Scientific Officer, said, "Good science is the foundation of Regeneron and long-term success in the biotechnology industry, and it is gratifying that our investments in science and technology over many years are helping patients."
Robert Terifay, Senior Vice President, Commercial, said, "We thank Scrip for this recognition and, most fundamentally, the patients and physicians who are behind the U.S. market acceptance of EYLEA® (aflibercept) Injection, which is now indicated in the U.S. for two eye diseases and which earlier this week was also approved in the European Union."
Award winners were selected by a 16-member panel of leading pharmaceutical industry executives, consultants, and researchers. More information about the panel is available here: http://www.scripintelligence.com/awards/judges/.
About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi. Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727. Regeneron has active research and development programs in many disease areas, including ophthalmology,
inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.
SOURCE Regeneron Pharmaceuticals, Inc.
